Sustained Release Intraocular Drug Delivery Devices for Treatment of Uveitis

Corticosteroids have been the mainstay of uveitis therapy. when intraocular inflammation is unresponsive to steroids, or steroid related side effects become a concern, steroid-sparing medications may be administered which can be classified into immunosuppressive and immunomodulatory agents. uveitis treatment can be delivered systemically, topically, periocularly or intraocularly. all of the above mentioned medications can entail significant systemic side effects, particularly if administered for prolonged durations, which may become treatment-limiting. some medications, particularly hydrophobic compounds, may poorly cross the blood-retinal barrier. topical medications, which have the least side effects, do not penetrate well into the posterior segment and are unsuitable for posterior uveitis which is often sight-threatening. intraocular or periocular injections can deliver relatively high doses of drug to the eye with few or no systemic side effects. however, such injections are associated with significant complications and must often be repeated at regular intervals. compliance with any form of regular medication can be a problem, particularly if its administration is associated with discomfort or if side effects are unpleasant. to overcome the above-mentioned limitations, an increasing number of sustained-release drug delivery devices using different mechanisms and containing a variety of agents have been developed to treat uveitis. this review discusses various current and future sustained-release ophthalmic drug delivery systems for treatment of uveitis